ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
담도암 시장 규모는 최근 몇 년 동안 강력하게 성장하고 있습니다. 2024년 6억 7,000만 달러에서 2025년에는 7억 2,000만 달러에 달하고, CAGR 7.2%를 나타낼 전망입니다. 실적기간의 성장은 담도암의 이환율 증가, 효과적인 치료법에 대한 수요 증가, 비만 등의 위험인자 증가, 인구 고령화, 연구개발 투자 증가 등으로 인한 것으로 예측됩니다.
담도암 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 7.1%를 나타내 9억 5,000만 달러로 성장할 전망입니다. 예측기간의 성장은 라이프스타일의 변화, 의식의 높아짐, 조기 발견에의 대처, 유리한 상환 정책, 정부 정책의 성장에 기인하는 것으로 예측됩니다. 예측기간의 주요 동향으로는 진단·치료에 있어서의 기술진보, 면역요법의 채용, 정밀의료에 대한 수요의 높아짐, 치료 어프로치의 진화, 바이오마커에 근거한 치료의 개발 등을 들 수 있습니다.
담도암(BTC)은 담관암으로도 알려져 있으며, 담관, 담낭 또는 Vater 방대부에서 발생하는 드문 악성 종양입니다. 이 암은 소화와 노폐물의 배설에 필수적인 담즙의 흐름을 억제합니다. 연구와 치료는 조기 발견, 치료법의 진보, 이환 환자의 생존율 향상에 중점을 둡니다.
담도암의 주된 유형은 간내 담관암, 간외담관암, 담낭암 등이 있습니다. 간내 담관암은 담관을 침범하는 드문 간암으로 담즙의 흐름이 멈출 수 있습니다. 치료 옵션은 화학요법, 표적요법, 면역요법 등이 있으며, 병원, 전문암센터, 외래수술센터 등 다양한 최종 사용자를 지원합니다.
2025년 봄 미국 관세의 급상승과 이에 따른 무역 마찰은 의료 분야, 특히 필수적인 의료기기, 진단 장비 및 의약품 공급에 큰 영향을 미쳤습니다. 병원과 건강 관리 제공업체는 수입되는 수술 기구, 영상 진단 시스템, 주사기 및 카테터와 같은 소모품의 비용 상승에 시달리고 있으며, 그 대부분은 국내 대체품이 제한되어 있습니다. 이러한 비용 상승이 의료 예산을 압박하기 때문에 일부 의료기관은 장비 업그레이드를 늦추거나 비용 증가를 환자에게 전가하고 있습니다. 게다가 원료와 부품에 대한 관세는 중요한 의약품과 의료기기의 제조에 지장을 주고 공급망의 지연으로 이어지고 있습니다. 이에 비해 업계는 다양한 조달 전략을 채택하고 가능한 한 현지 생산을 확대하고 중요한 의료 제품의 관세 면제를 수행하고 있습니다.
이 조사 보고서는 담도암 업계 세계 시장 규모, 지역 점유율, 담도암 시장 점유율을 가진 경쟁업체, 상세한 담도암 시장 부문, 시장 동향, 비즈니스 기회 등 담도암 시장 통계를 제공하는 The Business Research Company의 신간 보고서 시리즈 중 하나입니다. 이 담도암 시장 조사 보고서는 업계의 현재와 미래 시나리오를 자세히 분석하고 필요한 모든 것을 완벽한 관점에서 제공합니다.
향후 5년간의 성장률 7.1%라고 하는 예측은 전회의 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 인상은 네덜란드나 프랑스에서 조달하는 내시경적 역행성 담관 췌장관 조영(ERCP) 장치나 섬유아세포 증식 인자 수용체(FGFR) 억제제의 비용을 밀어 올려, 희소암의 치료비를 악화시켜, 치료 선택지를 제한함으로써, 미국의 암 센터에 부담을 줄 가능성이 높습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.
비만 유병률 상승이 담도암 시장 성장을 견인할 것으로 예측됩니다. 비만은 건강에 악영향을 미치는 과도한 지방 축적을 특징으로하는 만성 병리입니다. 비만률 증가에는 운동 부족, 심리적 영향, 노화, 유전적 및 생물학적 요인 등 여러 요인이 관여하고 있습니다. 비만은 만성 염증, 인슐린 저항성, 과도한 담즙산 분비를 촉진하여 DNA 손상과 종양 형성으로 이어집니다. 또한 호르몬 균형과 대사를 방해하여 담도 내에 암이 발생하기 쉬운 환경을 만듭니다. 예를 들어 2023년 9월 미국 정부기관인 질병대책예방센터(CDC)에 따르면 2022년 성인 비만률이 35% 이상인 주는 2021년 19주에서 22주로 증가했습니다. 그 결과 비만의 만연이 담도암 시장 확대에 박차를 가하고 있습니다.
담도암 시장 주요 기업은 치료 효과와 환자 결과를 개선하기 위해 고급 병용 요법을 개발하고 있습니다. 병용 요법은 둘 이상의 약물과 치료 접근법을 동시에 사용하여 효과를 향상시키는 것입니다. 예를 들어, 2023년 11월 미국 제약사 머크 앤드 컴퍼니(Merck & Co. Inc.)는 국소 진행성 절제 불가능 또는 전이성 담도암(BTC) 환자 치료를 위해 켐트루다(KEYTRUDA, 펨브롤리주맙)를 젬시타빈 및 시스플라틴과 병용하는 요법에 대해 미국 식품의약국(FDA)의 승인을 획득했습니다. 이 승인은 3상 KEYNOTE-966 시험의 결과에 근거하여 화학요법 단독에 비해 전체 생존 기간이 통계적으로 유의하게 개선되었고 사망 위험이 17% 감소했습니다. 병용요법을 받은 환자의 전체 생존기간 중앙값은 12.7개월이며, 화학요법 단독요법을 받은 환자의 10.9개월과 비교하여 이 과제인 암 치료 옵션에 큰 진보를 가져왔습니다.
2022년 12월, 아일랜드에 본사를 둔 제약회사 재즈 퍼머슈티컬즈 plc는 HER2 표적 이중특이적 항체인 자니다타마브의 개발·상품화로 자이메웍스사와 제휴했습니다. 이 제휴는 담도암을 대상으로 한 HERIZON-BTC-01 피보탈 시험의 유망한 결과에 의해 추진되었습니다. Zymeworks Inc.는 캐나다에 본사를 둔 생명공학 기업으로 담도암 의약품 개발에 특화되어 있습니다.
담도암 시장은 진단·스크리닝 서비스, 지지요법, 임상시험, 조사 등의 서비스를 제공하는 사업체가 얻는 수익으로 구성되어 있습니다. 시장 가치에는 서비스 제공업체가 판매하거나 서비스 제공에 포함된 관련 상품의 가치도 포함됩니다. 담도암 시장에는 수술기구, 통증 관리 약물, 진단 도구 판매도 포함됩니다. 이 시장의 가치는 '팩토리게이트(공장 출하 시)' 가치, 즉 제품 제조업체 또는 제조업체가 다른 기업(강하 제조업체, 도매업체, 유통업체, 소매업체 포함) 또는 직접 최종 고객에게 판매한 상품의 가치입니다. 이 시장에서 상품의 가치에는 상품 제작자에 의해 판매되는 관련 서비스도 포함됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 담도암 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 담도암 시장 : 성장률 분석
세계의 담도암 시장 실적 : 규모와 성장(2019-2024년)
세계의 담도암 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 담도암 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 담도암 시장: 암 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
간내 담관암
간외 담관암
담낭암
세계의 담도암 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
화학요법
표적 치료
면역 치료
세계의 담도암 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
전문 암 센터
외래수술센터(ASC)
기타 최종 사용자
세계의 담도암 시장 : 간내 담관암 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
주변 간내 담관암
간문부 간내 담관암
세계의 담도암 시장 : 간외 담관암 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
간문부 담관암
원위 담관암
세계의 담도암 시장 : 담낭암 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
국소성 담낭암
진행성 담낭암
제7장 지역별/국가별 분석
세계의 담도암 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 담도암 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
담도암 시장 : 경쟁 구도
담도암 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
AstraZeneca Plc
Eli Lily and Company
Boehringer Ingelheim International GmbH
Eisai Co. Ltd.
Servier Pharmaceuticals
Jazz Pharmaceuticals plc
Incyte Corporation
BeiGene LTD.
Zymeworks
Basilea Pharmaceutica Ltd.
Taiho Oncology Inc.
RenovoRx Inc.
TransThera Sciences Inc.
QED Therapeutics Inc.
Helsinn Group
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
담도암 시장(2029년) : 새로운 기회를 제공하는 국가
담도암 시장(2029년) : 새로운 기회를 제공하는 부문
담도암 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
Biliary tract cancer (BTC), also known as cholangiocarcinoma, is a rare malignancy that develops in the bile ducts, gallbladder, or ampulla of Vater. This cancer disrupts bile flow, which is essential for digestion and waste elimination. Research and treatment efforts focus on early detection, advancing therapeutic options, and improving survival rates for affected patients.
The primary types of biliary tract cancer include intrahepatic bile duct cancer, extrahepatic bile duct cancer, and gallbladder cancer. Intrahepatic cholangiocarcinoma is a rare liver cancer affecting the bile ducts, potentially leading to bile flow obstruction. Treatment options include chemotherapy, targeted therapy, and immunotherapy, catering to various end users such as hospitals, specialty cancer centers, ambulatory surgical centers, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The biliary tract cancer market research report is one of a series of new reports from The Business Research Company that provides biliary tract cancer market statistics, including the biliary tract cancer industry global market size, regional shares, competitors with the biliary tract cancer market share, detailed biliary tract cancer market segments, market trends, and opportunities, and any further data you may need to thrive in the biliary tract cancer industry. This biliary tract cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The biliary tract cancer market size has grown strongly in recent years. It will grow from $0.67 billion in 2024 to $0.72 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to the increasing incidence of biliary tract cancer, growing demand for effective therapies, a rise in risk factors such as obesity, an aging population, and increasing investment in research and development.
The biliary tract cancer market size is expected to see strong growth in the next few years. It will grow to $0.95 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to lifestyle changes, growing awareness, early detection initiatives, favorable reimbursement policies, and growing government policies. Major trends in the forecast period include technological advancements in diagnosis and treatment, adoption of immunotherapy, rising demand for precision medicine, evolving treatment approaches, and development in biomarker-based therapies.
The forecast of 7.1% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. cancer centers by driving up the cost of Endoscopic Retrograde Cholangiopancreatography(ERCP) devices and Fibroblast Growth Factor Receptor (FGFR) inhibitors sourced from the Netherlands and France, exacerbating rare cancer treatment costs and limiting therapeutic options. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising prevalence of obesity is expected to drive the growth of the biliary tract cancer market. Obesity is a chronic medical condition characterized by excessive fat accumulation that negatively impacts health. Several factors contribute to the increasing obesity rates, including physical inactivity, psychological influences, aging, and genetic or biological factors. Obesity promotes chronic inflammation, insulin resistance, and excessive bile acid secretion, leading to DNA damage and tumor formation. It also disrupts hormonal balance and metabolism, creating a cancer-prone environment in the biliary tract. For example, in September 2023, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that in 2022, the number of states with an adult obesity rate of 35% or higher increased to 22, up from 19 in 2021. As a result, the growing prevalence of obesity is fueling the expansion of the biliary tract cancer market.
Leading companies in the biliary tract cancer market are developing advanced combination therapies to improve treatment efficacy and patient outcomes. Combination therapy involves using two or more medications or treatment approaches simultaneously to enhance effectiveness. For instance, in November 2023, Merck & Co. Inc., a US-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for KEYTRUDA (pembrolizumab) in combination with gemcitabine and cisplatin for treating patients with locally advanced unresectable or metastatic biliary tract cancer (BTC). This approval was based on results from the Phase 3 KEYNOTE-966 trial, which demonstrated a statistically significant improvement in overall survival, reducing the risk of death by 17% compared to chemotherapy alone. Patients receiving the combination therapy had a median overall survival of 12.7 months, compared to 10.9 months for those on chemotherapy alone, marking a major advancement in treatment options for this challenging cancer.
In December 2022, Jazz Pharmaceuticals plc, an Ireland-based pharmaceutical company, partnered with Zymeworks Inc. to develop and commercialize zanidatamab, a HER2-targeted bispecific antibody. This collaboration was driven by promising results from the HERIZON-BTC-01 pivotal trial for biliary tract cancers. Zymeworks Inc. is a Canada-based biotechnology company specializing in the development of biliary tract cancer drugs.
Major players in the biliary tract cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Eli Lily and Company, Boehringer Ingelheim International GmbH, Eisai Co. Ltd., Servier Pharmaceuticals, Jazz Pharmaceuticals plc, Incyte Corporation, BeiGene LTD., Zymeworks, Basilea Pharmaceutica Ltd., Taiho Oncology Inc., RenovoRx Inc., TransThera Sciences Inc., QED Therapeutics Inc., and Helsinn Group.
North America was the largest region in the biliary tract cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in biliary tract cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the biliary tract cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The biliary tract cancer market consists of revenues earned by entities by providing services such as diagnosis and screening services, supportive care, clinical trials, and research. The market value includes the value of related goods sold by the service provider or included within the service offering. The biliary tract cancer market also includes sales of surgical instruments, pain management medications, and diagnostic tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Biliary Tract Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on biliary tract cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for biliary tract cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biliary tract cancer market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Cancer Type: Intrahepatic Bile Duct Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer
2) By Treatment: Chemotherapy; Targeted Therapy; Immunotherapy
3) By End-User: Hospitals; Specialty Cancer Centres; Ambulatory Surgical Centres; Other End-Users
Subsegments:
1) By Intrahepatic Bile Duct Cancer: Peripheral Intrahepatic Bile Duct Cancer; Hilar Intrahepatic Bile Duct Cancer
2) By Extrahepatic Bile Duct Cancer: Perihilar Bile Duct Cancer; Distal Bile Duct Cancer
3) By Gallbladder Cancer: Localized Gallbladder Cancer; Advanced Gallbladder Cancer
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bayer AG; Bristol-Myers Squibb Company; AstraZeneca Plc; Eli Lily and Company; Boehringer Ingelheim International GmbH; Eisai Co. Ltd.; Servier Pharmaceuticals; Jazz Pharmaceuticals plc; Incyte Corporation; BeiGene LTD.; Zymeworks; Basilea Pharmaceutica Ltd.; Taiho Oncology Inc.; RenovoRx Inc.; TransThera Sciences Inc.; QED Therapeutics Inc.; Helsinn Group
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Biliary Tract Cancer Market Characteristics
3. Biliary Tract Cancer Market Trends And Strategies
4. Biliary Tract Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Biliary Tract Cancer Growth Analysis And Strategic Analysis Framework
5.1. Global Biliary Tract Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Biliary Tract Cancer Market Growth Rate Analysis
5.4. Global Biliary Tract Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Biliary Tract Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Biliary Tract Cancer Total Addressable Market (TAM)
6. Biliary Tract Cancer Market Segmentation
6.1. Global Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intrahepatic Bile Duct Cancer
Extrahepatic Bile Duct Cancer
Gallbladder Cancer
6.2. Global Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Targeted Therapy
Immunotherapy
6.3. Global Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Cancer Centres
Ambulatory Surgical Centres
Other End-Users
6.4. Global Biliary Tract Cancer Market, Sub-Segmentation Of Intrahepatic Bile Duct Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Peripheral Intrahepatic Bile Duct Cancer
Hilar Intrahepatic Bile Duct Cancer
6.5. Global Biliary Tract Cancer Market, Sub-Segmentation Of Extrahepatic Bile Duct Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Perihilar Bile Duct Cancer
Distal Bile Duct Cancer
6.6. Global Biliary Tract Cancer Market, Sub-Segmentation Of Gallbladder Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Localized Gallbladder Cancer
Advanced Gallbladder Cancer
7. Biliary Tract Cancer Market Regional And Country Analysis
7.1. Global Biliary Tract Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Biliary Tract Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Biliary Tract Cancer Market
8.1. Asia-Pacific Biliary Tract Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Biliary Tract Cancer Market
9.1. China Biliary Tract Cancer Market Overview
9.2. China Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Biliary Tract Cancer Market
10.1. India Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Biliary Tract Cancer Market
11.1. Japan Biliary Tract Cancer Market Overview
11.2. Japan Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Biliary Tract Cancer Market
12.1. Australia Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Biliary Tract Cancer Market
13.1. Indonesia Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Biliary Tract Cancer Market
14.1. South Korea Biliary Tract Cancer Market Overview
14.2. South Korea Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Biliary Tract Cancer Market
15.1. Western Europe Biliary Tract Cancer Market Overview
15.2. Western Europe Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Biliary Tract Cancer Market
16.1. UK Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Biliary Tract Cancer Market
17.1. Germany Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Biliary Tract Cancer Market
18.1. France Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Biliary Tract Cancer Market
19.1. Italy Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Biliary Tract Cancer Market
20.1. Spain Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Biliary Tract Cancer Market
21.1. Eastern Europe Biliary Tract Cancer Market Overview
21.2. Eastern Europe Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Biliary Tract Cancer Market
22.1. Russia Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Biliary Tract Cancer Market
23.1. North America Biliary Tract Cancer Market Overview
23.2. North America Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Biliary Tract Cancer Market
24.1. USA Biliary Tract Cancer Market Overview
24.2. USA Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Biliary Tract Cancer Market
25.1. Canada Biliary Tract Cancer Market Overview
25.2. Canada Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Biliary Tract Cancer Market
26.1. South America Biliary Tract Cancer Market Overview
26.2. South America Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Biliary Tract Cancer Market
27.1. Brazil Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Biliary Tract Cancer Market
28.1. Middle East Biliary Tract Cancer Market Overview
28.2. Middle East Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Biliary Tract Cancer Market
29.1. Africa Biliary Tract Cancer Market Overview
29.2. Africa Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Biliary Tract Cancer Market Competitive Landscape And Company Profiles
30.1. Biliary Tract Cancer Market Competitive Landscape
30.2. Biliary Tract Cancer Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
31. Biliary Tract Cancer Market Other Major And Innovative Companies
31.1. AstraZeneca Plc
31.2. Eli Lily and Company
31.3. Boehringer Ingelheim International GmbH
31.4. Eisai Co. Ltd.
31.5. Servier Pharmaceuticals
31.6. Jazz Pharmaceuticals plc
31.7. Incyte Corporation
31.8. BeiGene LTD.
31.9. Zymeworks
31.10. Basilea Pharmaceutica Ltd.
31.11. Taiho Oncology Inc.
31.12. RenovoRx Inc.
31.13. TransThera Sciences Inc.
31.14. QED Therapeutics Inc.
31.15. Helsinn Group
32. Global Biliary Tract Cancer Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Biliary Tract Cancer Market
34. Recent Developments In The Biliary Tract Cancer Market
35. Biliary Tract Cancer Market High Potential Countries, Segments and Strategies
35.1 Biliary Tract Cancer Market In 2029 - Countries Offering Most New Opportunities
35.2 Biliary Tract Cancer Market In 2029 - Segments Offering Most New Opportunities
35.3 Biliary Tract Cancer Market In 2029 - Growth Strategies
